 I. To determine the R0 complete resection resection rate for subjects with borderline resectable or lymph node positive pancreatic adenocarcinoma treated with a multimodality neoadjuvant therapy of preoperative gemcitabine gemcitabine hydrochloride and ABRAXANE nab-paclitaxel followed by 5-fluorouracil fluorouracil based image-guided intensity-modulated radiation therapy IG-IMRT chemoradiotherapy. 